LEE'S PHARM (00950.HK): Buys USD 7.67M Staccato Heater Line
NewTimeSpace News: On 19 November 2026, Lee's Pharmaceutical Holdings Limited (stock code: 00950) announced that its indirectly wholly-owned subsidiary, Nova Pneuma Incorporated, placed a purchase order with Automation Tool Company on 18 November 2026 (after trading hours) to acquire a tailor-made automated heating component assembly line at a consideration of up to USD 7,668,400 (about HKD 59,814,000), depending on additional options for the equipment.
The assembly line is used to manufacture heating components that form part of the Staccato device and integrates robotic procedures to produce fully assembled products. It will be installed and delivered at the facility of the facility operator, Daicel Safety Systems Americas, in Mesa, Arizona, the United States. The facility operator is the buyer's manufacturing partner and is responsible for providing the manufacturing facility and taking part in design reviews, acceptance testing, installation and commissioning.
Thirty per cent of the consideration is payable as a down payment within 10 days of the purchase order date, with the remainder paid in instalments according to the assembly and testing status of the equipment and the balance due within 30 days after completion of site acceptance testing. Delivery is expected about 50 weeks after the seller accepts the order, with a 12-month standard warranty after installation. The seller, the facility operator and their respective ultimate beneficial owners are independent third parties, and the consideration will be funded from the group's available financial resources.
The directors said the acquisition will enhance the group's manufacturing capability for heating components used in Staccato products, raising capacity, improving manufacturing efficiency and reducing reliance on manual procedures to support future business growth and commercialisation plans. As one or more applicable percentage ratios exceed 5% but are below 25%, the transaction constitutes a discloseable transaction under Chapter 14 of the Listing Rules and is subject to notification and announcement requirements.
- LEE'S PHARM (00950.HK): In-Licenses PARP1 Inhibitor OC-3 from 1cBio for Development and Commercialization in Greater China and Southeast Asia
- Lee's Pharmaceutical Holdings Limited (00950.HK): IND Application for Proprietary ADC Asset ZK2401 Accepted by NMPA in China
- Lee's Pharmaceutical Holdings (00950.HK): Enters Exclusive Licence Agreement with Ashlins for Interferon Alpha-2b for Regions Outside Greater China